Millipore Sigma Vibrant Logo

500506 EPAC Inhibitor, ESI-09 - CAS 263707-16-0 - Calbiochem

A cell-permeable compound that targets cAMP-binding domain of EPAC/cAMP-GEF and inhibits cAMP-dependent EPAC GEF activity (IC₅₀ = 1.4 and 3.2 µM, respectively, against EPAC2 and EPAC1).

MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.

Synonyms: Exchange Protein Directly Activated by cAMP Inhibitor, 3-(5-tert-butyl-isoxazol-3-yl)-2-((3-chlorophenyl)-hydrazono)-3-oxo-propionitrile, cAMP -GEF Inhibitor

View Products on Sigmaaldrich.com
500506
View Pricing & Availability

Overview

Replacement Information

Key Specifications Table

CAS #Empirical Formula
263707-16-0C₁₆H₁₅ClN₄O2

Pricing & Availability

Catalog Number AvailabilityPackaging Qty/Pack Price Quantity
5.00506.0001
Retrieving availability...
—
Limited Availability Limited Availability
Stocked 
Discontinued
Limited Quantities Available
Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

      		 Glass bottle 10 mg
      Retrieving price...
      Price could not be retrieved
      Minimum Quantity is a multiple of
      Maximum Quantity is
      Upon Order Completion More Information
      You Saved ()
       
      —
      Request Pricing
      		 —
      Description
      OverviewA cell-permeable propionitrile compound that targets the CBD (cAMP-binding domain) of EPAC/cAMP-GEF with 4-fold higher affinity than cAMP and selectively inhibits cAMP-dependent EPAC GEF activity (IC50 = 1.4 and 3.2 µM, respectively, against EPAC2 and EPAC1; [cAMP] = 25 µM) with much reduced potency toward cAMP-dependent PKA activity (10% and 20% inhibition at 100 µM, respectively, against 100 µM cAMP-stimulated Type Iα and IIβ PKA activity). Shown to block both basal and 8-CPT-2'-O-Me-cAMP (Cat. No. 116833) prodrug 007-AM-, but not EGF-, stimulated Akt phosphorylations in serum-starved human AsPC-1 (≥185%, ≤85%, and <10% of basal thr308/Ser473 phosphorylation, respectively, with 0, 1, 10 µM ESI-09; [007-AM] = 10 µM) and EPAC-mediated insulin secretion from rat INS-1 cells (IC50 <5 µM; [007-AM] = 10 µM).
      Catalogue Number500506
      Brand Family Calbiochem®
      SynonymsExchange Protein Directly Activated by cAMP Inhibitor, 3-(5-tert-butyl-isoxazol-3-yl)-2-((3-chlorophenyl)-hydrazono)-3-oxo-propionitrile, cAMP -GEF Inhibitor
      References
      ReferencesAlmahariq, M., et al. 2013. Mol Pharmacol. 83, 122.
      Product Information
      CAS number263707-16-0
      FormYellow powder
      Hill FormulaC₁₆H₁₅ClN₄O2
      Chemical formulaC₁₆H₁₅ClN₄O2
      Quality LevelMQ100
      Applications
      Biological Information
      Purity≥98% by HPLC
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Shipped at Ambient Temperature or with Blue Ice or with Dry Ice
      Toxicity Standard Handling
      Storage +2°C to +8°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Catalog Number GTIN
      5.00506.0001 04055977245691

      Documentation

      EPAC Inhibitor, ESI-09 - CAS 263707-16-0 - Calbiochem SDS

      Title

      Safety Data Sheet (SDS) 

      EPAC Inhibitor, ESI-09 - CAS 263707-16-0 - Calbiochem Certificates of Analysis

      TitleLot Number
      500506

      References

      Reference overview
      Almahariq, M., et al. 2013. Mol Pharmacol. 83, 122.
      Data Sheet

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision28-April-2014 JSW
      SynonymsExchange Protein Directly Activated by cAMP Inhibitor, 3-(5-tert-butyl-isoxazol-3-yl)-2-((3-chlorophenyl)-hydrazono)-3-oxo-propionitrile, cAMP -GEF Inhibitor
      DescriptionA cell-permeable, propionitrile compound that targets the CBD (cAMP-binding domain) of EPAC/cAMP-GEF with 4-fold higher affinity than cAMP (IC50 = 10 vs. 39 µM, respectively, against 8-NBD-cAMP in competition EPAC2 binding assay) and selectively inhibits cAMP-dependent EPAC GEF activity (IC50 = 1.4 and 3.2 µM, respectively, against EPAC2 and EPAC1; [cAMP] = 25 µM) with much reduced potency toward cAMP-dependent PKA activity (10% and 20% inhibition at 100 µM, respectively, against 100 µM cAMP-stimulated Type Iα and IIβ PKA activity). Shown to block both basal and 8-CPT-2'-O-Me-cAMP (Cat. No. 116833) prodrug 007-AM-stimulated Akt thr308/Ser473 phosphorylations in serum-starved human pancreatic cancer AsPC-1 (%thr308/%Ser473 of basal phosphorylation = 200%/185%, 85%/65%, and <10%/<10%, respectively, with 0, 1, 10 µM ESI-09; [007-AM] = 10 µM) and rat pancreatic β-cell INS-1 without affecting EGF-stimulated Akt phosphorylations, resulting in effective inhibition of EPAC-mediated insulin secretion from INS-1 cells (by 57% and 100%, respectively, at 5 and 10 µM; [007-AM] = 10 µM) and pancreatic cancer cell invasion (~60% inhibition at 5 µM using AsPC-1 and PANC-1 cells).
      FormYellow powder
      Intert gas (Yes/No) Packaged under inert gas
      CAS number263707-16-0
      Chemical formulaC₁₆H₁₅ClN₄O2
      Purity≥98% by HPLC
      SolubilityDMSO (100 mg/ml)
      Storage Protect from light
      +2°C to +8°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Toxicity Standard Handling
      ReferencesAlmahariq, M., et al. 2013. Mol Pharmacol. 83, 122.